Immunovant (IMVT) earnings history
Most recent quarter
- Fiscal period
- Q1 2027
- Period end
- Jun 30, 2026
- EPS actual
- −$0.75
- EPS estimate
- −$0.63
- EPS surprise
- −19.26%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 6, 2026
Immunovant's fiscal year differs from the calendar year, so its fiscal Q1 2027 results were reported on August 6, 2026. The company posted a loss of $0.75 per share, wider than the $0.63 loss analysts expected, a 19.26% miss. The table gives no revenue figure or revenue estimate for this quarter or any other. Compared with fiscal Q1 2026, the loss widened from $0.71 per share, about 6%.
Every quarter in the table is a loss, and losses have grown over time. The annual loss was $1.71 per share in fiscal 2023, $1.83 in fiscal 2024, $2.74 in fiscal 2025 and $2.78 in fiscal 2026. The narrowest quarterly loss shown is $0.29 in fiscal Q3 2024. The widest is $0.76 in fiscal Q3 2025. Over the last six quarters the loss has stayed between $0.61 and $0.75 per share. Immunovant missed the EPS estimate in 15 of the last 20 quarters, including the latest two.
The company reported its fiscal Q2 results between November 4 and November 10 in each of the past five years. That points to early or mid November 2026 for the next report. It will show whether the loss stays in that range.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q1 2027 | Aug 6, 2026 | −$0.63 | −$0.75 | −19.26% | $0.00 | SEC |
| Q4 2026 | May 20, 2026 | −$0.59 | −$0.73 | −23.31% | $0.00 | SEC |
| Q3 2026 | Feb 6, 2026 | −$0.71 | −$0.61 | +14.49% | $0.00 | SEC |
| Q2 2026 | Nov 10, 2025 | −$0.71 | −$0.73 | −2.21% | $0.00 | SEC |
| Q1 2026 | Aug 11, 2025 | −$0.68 | −$0.71 | −4.35% | $0.00 | SEC |
| Q4 2025 | May 29, 2025 | −$0.71 | −$0.64 | +10.28% | $0.00 | SEC |
| Q3 2025 | Feb 6, 2025 | −$0.75 | −$0.76 | −1.10% | $0.00 | SEC |
| Q2 2025 | Nov 7, 2024 | −$0.60 | −$0.74 | −23.29% | $0.00 | SEC |
| Q1 2025 | Aug 6, 2024 | −$0.53 | −$0.60 | −13.08% | $0.00 | SEC |
| Q4 2024 | May 29, 2024 | −$0.43 | −$0.52 | −21.04% | $0.00 | SEC |
| Q3 2024 | Feb 12, 2024 | −$0.43 | −$0.29 | +32.35% | $0.00 | SEC |
| Q2 2024 | Nov 9, 2023 | −$0.46 | −$0.45 | +1.77% | $0.00 | SEC |
| Q1 2024 | Aug 10, 2023 | −$0.45 | −$0.57 | −27.72% | $0.00 | SEC |
| Q4 2023 | May 22, 2023 | −$0.42 | −$0.46 | −8.80% | $0.00 | SEC |
| Q3 2023 | Feb 3, 2023 | −$0.37 | −$0.49 | −31.33% | $0.00 | SEC |
| Q2 2023 | Nov 4, 2022 | −$0.37 | −$0.41 | −10.78% | $0.00 | SEC |
| Q1 2023 | Aug 5, 2022 | −$0.37 | −$0.35 | +6.54% | $0.00 | SEC |
| Q4 2022 | Jun 8, 2022 | −$0.36 | −$0.41 | −13.35% | $0.00 | SEC |
| Q3 2022 | Feb 4, 2022 | −$0.32 | −$0.36 | −12.92% | $0.00 | SEC |
| Q2 2022 | Nov 5, 2021 | −$0.26 | −$0.35 | −33.13% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Immunovant (IMVT) last report earnings?
Immunovant last reported on Aug 6, 2026, covering fiscal Q1 2027.
Did IMVT beat earnings estimates?
No. Immunovant reported EPS of −$0.75 for Q1 2027 against a −$0.63 estimate — a 19.26% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.